<DOC>
	<DOCNO>NCT01129479</DOCNO>
	<brief_summary>Cognitive impairment stroke common major effect morbidity quality life . Acetylcholinesterase inhibitor demonstrate benefit vascular dementia , efficacy treat circumscribe cognitive deficit follow stroke , aphasia , systematically investigate . This study evaluate efficacy Galantamine ( Reminyl ) subject chronic , stable non-fluent aphasia secondary stroke . Subjects enrol double-blind placebo- control cross-over study employ comprehensive battery language test measure general cognitive behavioral status use control factor may influence language functioning . The primary study outcome within-subject comparison change language function behavioral score placebo active-treatment phase ( 12 week ) . Our hypothesis increase acetylcholine level , facilitate activity neurotransmitter affect attentional system , Galantamine would produce gain language behavioral score patient suffer chronic effect cognitive system due injury follow stroke .</brief_summary>
	<brief_title>Galantamine Treatment Nonfluent Aphasia Stroke Patients</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Aphasia</mesh_term>
	<mesh_term>Aphasia , Broca</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>Diagnosis aphasia relatively spared comprehension . Onset 6 month great prior enrollment . Native English speaker Righthanded . Adults ( 18 year age old ) . Patients receive ongoing individual speech therapy . ( Most patient longer eligible individualized speech therapy 6 month stroke onset , thus eliminate many patient ) . Extremely mild extremely severe aphasia . ( Boston Naming Test Score &lt; 3 &gt; 45 item name 60 item ) . Global dementia ( patient reduce decisional capacity require legally authorize representative consent ) . Presence major cognitive deficit aphasia cause stroke related disease . Contraindications cholinomimetic agent : History active peptic ulcer disease within 1 year , Severe asthma , unstable angina , bradyarrhythmia rest pulse less 50 , sick sinus syndrome , seizure . Major psychiatric disorder affect cognition include : psychosis , major depression , bipolar disorder , alcohol substance abuse . Major medical condition alter cognition ( e.g. , heart failure , dialysis dependent renal failure , hepatic failure , active cancer ) . Impairments affect metabolism medication include : Severe renal impairment ( Creatinine clearance equal great 9 ) , moderate severe hepatic impairment ( ChildPugh score &gt; 7 ) Patients use medication major effect brain neurotransmitter system cognition within 2 month enrollment . Exclusionary medication : medication significant anticholinergic activity ( tricyclic antidepressant , diphenhydramine ) , antiParkinsonian medication ( include Sinemet , amantadine , bromocriptine , pergolide , selegiline ) , narcotic analgesic ( &gt; 2 dos per week ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Aphasia</keyword>
	<keyword>treatment</keyword>
	<keyword>cholinesterase inhibitor</keyword>
	<keyword>stroke</keyword>
</DOC>